

8TH ANNUAL **EMSCO** MEETING 2021 NOVEMBER 5

Virtual Meeting

WITH INSTITUTIONAL SUPPORT

abbvie

astex

Celgene | Bristol Myers Squibb
Company

NOVARTIS | Reimagining Medicine

janssen Oncology

Takeda

D-MDS
Deutsche MDS-Studien-gruppe

EMSCO
European Myelodysplastic Syndromes
Cooperative Group

gfm
Groupe
Francophone des
Myélodysplasies

Preliminary Program

8TH EMSCO annual meeting 2021

November 5 - 2021

Session 1: EMSCO trial update

- 8:30 PM : Update on ongoing trials
- 9:00 PM : EMSCO trials in the pipeline
- 9:30 PM : Snapshot of current global clinical research in MDS
- 10:00 PM : Regulatory aspects of clinical trials

break (10:30 - 11:00)

Session 2: Pathophysiology & prognosis

- 11:00 PM : Stem cell hierarchy in MDS - different than expected?
- 11:30 PM : Niche and MDS: druggable targets?
- 12:00 PM : Iron in MDS: fake or fact ?
- 12:30 PM : Molecular prognostic markers in MDS and AML

break (13:00 - 14:00)

Session 3 : Therapy of MDS and AML

- 14:00 : Standards and perspectives of treatment in lower-risk MDS
- 14:30 : HMAs in MDS and AML. Isn't there any biomarker of outcome and response ?
- 15:00 : There are any novel concepts of allogeneic transplant in MDS ?

break (15:30 - 16:00)

Session 4: New targets in MDS and AML

- 16:00 : How to improve of high-risk and AML in the elderly ?
- 16:30 : IDH1 and 2 revisited - a druggable target with curative potential ?
- 17:00 : Moving from bench to bedside in myeloid malignancies : the futur of AML/MDS ?

Registration free but required : <http://meetingvirtuel.com/>

Local Organizer :
CHU Nice-Hopital de l'Archet 1
Pr Thomas CLUZEAU
151 route de Ginestière
Tel : +33-4.92.03.90-87
Email : cluzeau.t@chu-nice.fr

Logistics Organization :
Canopée Communication
Sylvie CUVILLIER
516 Les Laures-44 330 VALLET
Tel : +33-6 77 99 01 01
Email : cuvillier@canopeedeveloppement.com